LIBTAYO as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.

LIBTAYO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).

For full details please refer to the PI as approved by the IL MoH

Encorafenib is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

For full details please refer to the PI as approved by the IL MoH

KIMMTRAK is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

For full details please refer to the PI as approved by the IL MoH